What is SparingVision?
SparingVision is dedicated to the field of genomic medicine, with a core mission to develop and deliver vision-saving treatments. The company leverages cutting-edge science to address a range of ocular conditions, aiming to significantly improve the quality of life for patients suffering from vision impairment. Its focus on pioneering science positions it at the forefront of innovation in ophthalmology and genetic therapies.
How much funding has SparingVision raised?
SparingVision has raised a total of $130.5M across 3 funding rounds:
Grant
$2.8M
Series A
$52.7M
Series B
$75M
Grant (2019): $2.8M with participation from European EIC Accelerator
Series A (2020): $52.7M led by Jeito Capital, University of Pittsburgh Medical Centre Enterprise, Ysios Capital, Bpifrance, Foundation Fighting Blindness, and 4BIO Capital
Series B (2022): $75M supported by 4BIO Capital, Bpifrance, Ysios Capital, Retinal Degeneration Fund, University of Pittsburgh Medical Center Enterprise, and Jeito
Key Investors in SparingVision
4BIO Capital
4BIO Capital is a London-based venture capital firm specializing in life sciences investments, focusing on advanced therapies that address significant unmet medical needs, including gene therapy and RNA-based therapies.
Bpifrance
Bpifrance is a French public investment bank that finances companies at every stage of their development, supporting innovation projects and international expansion.
Ysios Capital
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, providing resources to develop novel therapies for significant unmet medical needs.
What's next for SparingVision?
With the recent influx of capital, SparingVision is poised for accelerated growth and the advancement of its therapeutic pipeline. The major strategic investment suggests confidence from backers in the company's technology and market potential. Future endeavors will likely concentrate on progressing its genomic therapies through clinical trials, expanding its research capabilities, and potentially forging strategic partnerships to broaden its reach and impact in the global fight against vision loss. The company's trajectory indicates a strong focus on scaling operations and achieving key developmental milestones.
See full SparingVision company page
